# Effect of 2nd Gen TKI in CML

> **NCT02222272** · — · COMPLETED · sponsor: **European Society for Blood and Marrow Transplantation** · enrollment: 432 (actual)

## Conditions studied

- Myeloid Leukemia, Chronic

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02222272
- **Lead sponsor:** European Society for Blood and Marrow Transplantation
- **Sponsor class:** NETWORK
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01-01
- **Primary completion:** 2014-03-19
- **Final completion:** 2017-09-29
- **Target enrollment:** 432 (ACTUAL)
- **Last updated:** 2024-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02222272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02222272, "Effect of 2nd Gen TKI in CML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02222272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*